We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation ("the Company") (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the "Registration Statement"
Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”.